Incyte Corporation Stock News

Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.

Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte stock tumbled below its 200-day line Tuesday after sales of the company's new skin treatment lagged second-quarter expectations. The post Incyte Posts Strong Quarter For Cancer Drug; Here's Why

Incyte Corporation (NASDAQ:INCY ) Q2 2022 Earnings Conference Call August 2, 2022 8:00 AM ET Company Participants Christine Chiou – Head of Investor Relations Hervé Hoppenot – Chairman, President

Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.

Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 1 2 2 0 Last 30D 0 0 1

Upgrades According to Argus Research, the prior rating for Huntington Bancshares Inc (NASDAQ:HBAN) was changed from Hold to Buy. In the second quarter, Huntington Bancshares showed an EPS of $0.36, c

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -69.23% and 8.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.

The stock market is suffering a turbulent 2022 so far – and with inflation still running at a 40-year high, the Federal Reserve locked in a significant rate-hiking cycle and midterm elections just m

Their drug prospects are helping them perform better than most stocks on the market this year.

Their drug prospects are helping them perform better than most stocks on the market this year.

JMP Securities reiterated its Market Outperform rating and increased the price target to $113 from $108 for Incyte Corporation (NASDAQ: INCY) based on multiple discounted earnings per share and re

'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.